DiaMedica Therapeutics Inc.
DMACHealthcare|Biotechnology|US
$9.36
+0.32 (+3.54%)
DCF Value
$0.30
Tangible Book / Share
$0.71
Cash / Share
$0.81
Clinical Trials (7)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05065216 Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) | Acute Stroke, Ischemic Stroke | P2P3 | Recruiting | 728 | RCT, Double-blind | Recombinant human tissue kallikrein |
| NCT04123613 Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX) | Kidney Diseases | P2 | Completed | 79 | Open-label | DM199 |
| NCT01845064 A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients | Diabetes Type 2 | P1P2 | Completed | 98 | RCT, Double-blind | DM199, Placebo |
| NCT03290560 Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke | Acute Ischemic Stroke | P2 | Completed | 92 | RCT, Double-blind | Recombinant human tissue kallikrein |
| NCT03795389 Study to Assess PK, Safety and Tolerability in Patients With DM and CKD | Chronic Kidney Disease, Chronic Kidney Disease, Stage 3 (Moderate) | P1 | Completed | 33 | Open-label | DM199 |
| NCT02868996 An Open Label, Phase 1b, Ascending Dose Study of DM199 | Stroke | P1 | Completed | 36 | Open-label | Recombinant human tissue kallikrein |
| NCT06875141 DM199 for Pregnancy Complications | Pre-Eclampsia | N/A | Withdrawn | — | Open-label | DM199 |